Additional approaches may include specific inhibition of ATAD2-MKK3/6 interaction, which have the potential to reactivate p38 tumor suppressor function, and may benefit the large percentage of HCC patients with mutant p53. This evidence concerns the gene MAP2K3 and hepatocellular carcinoma.